Navigation Links
Volcano Corporation Schedules Second Quarter Conference Call, Webcast
Date:7/29/2008

SAN DIEGO, July 29 /PRNewswire-FirstCall/ -- Volcano Corporation (Nasdaq: VOLC), a leading manufacturer and developer of intravascular ultrasound (IVUS), functional measurement (FM) and Optical Coherence Tomography (OCT) products designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today announced that it will report its operating results for the second quarter and first six months of fiscal 2008 on Tuesday, August 5.

The company will hold a conference call to discuss its financial results and operating activities open to all interested parties at 2 p.m., Pacific Daylight Time, (5 p.m., Eastern Daylight Time), Tuesday, August 5, hosted by Scott Huennekens, president and chief executive officer, and John Dahldorf, chief financial officer.

The teleconference can be accessed by calling (719) 325-4886, passcode 4988988. Please dial in 10-15 minutes prior to the beginning of the call. The webcast will be available through the company's website at http://www.volcanocorp.com.

A replay of the conference call will be available through Monday, August 11, at (719) 457-0820, passcode 4988988, and via the company's website.

About Volcano Corporation

Volcano Corporation (NASDAQ: VOLC) offers a broad suite of devices designed to facilitate endovascular procedures, enhance the diagnosis of vascular and structural heart disease and guide optimal therapies. The company's intravascular ultrasound (IVUS) product line includes ultrasound consoles that can be integrated directly into virtually any modern cath lab. Volcano IVUS offers unique features, including both single-use phased array and rotational IVUS imaging catheters, and advanced functionality options, such as VH(TM) tissue characterization and ChromaFlo(R). Volcano also provides functional measurement (FM) consoles and single-use pressure and flow guide wires and is developing a line of ultra high-resolution Optical Coherent Tomography (OCT) systems and catheters. Currently, more than 3,300 Volcano IVUS and FM systems are installed worldwide with approximately half of its revenues coming from outside the United States. For more information, visit the company's website at http://www.volcanocorp.com.


'/>"/>
SOURCE Volcano Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Volcano Announces Acquisition of Novelis, Inc.
2. Volcano Announces Placement of 1,000th s5 and s5i IVUS Imaging System
3. Volcano Corp Announces First Human Use of the Volcano Optical Coherence Tomography (OCT) Imaging Catheter
4. Volcano Reports 24 Percent Increase in First Quarter Revenues; IVUS Disposable Revenues Increase 30 Percent
5. Volcano Announces U.S. and European Launch of Rotational IVUS and Integrated FFR
6. Volcano Corporation Presentation at Cowen Healthcare Conference to be Webcast
7. Volcano Announces FDA 510(k) Clearance of Revolution Rotational Catheter and FFR for the s5i Integrated IVUS Console
8. Volcano Corporation Schedules Fourth Quarter Conference Call, Webcast
9. Volcano Announces Closing of CardioSpectra Acquisition
10. Volcano Announces Activities at TCT 2007: Expanded Role of IVUS in PCI to be Demonstrated
11. Volcano Corporation Announces Pricing of Common Stock Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... BioMarketing, a leading provider of patient support solutions, has announced ... network, which will launch this week. The VMS CNEs will ... to enhance the patient care experience by delivering peer-to-peer education ... professionals to help women who have been diagnosed and are ... ...
(Date:10/11/2017)... ... ... Disappearing forests and increased emissions are the main causes of the evolving ... those living in larger cities are affected by air pollution related diseases. , That ... countries globally - decided to take action. , “I knew I had to take ...
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology today announced ... to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) B ... to cross the cell membrane and bind intracellular STAT3 and inhibit its function. ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give it ... Nanoparticle), a technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). ...
Breaking Biology Technology:
(Date:4/11/2017)... Research and Markets has announced the addition ... their offering. ... tracking market to grow at a CAGR of 30.37% during the ... 2017-2021, has been prepared based on an in-depth market analysis with ... its growth prospects over the coming years. The report also includes ...
(Date:4/5/2017)... 2017 Today HYPR Corp. , leading ... component of the HYPR platform is officially FIDO® ... security architecture that empowers biometric authentication across Fortune 500 ... secured over 15 million users across the financial services ... home product suites and physical access represent a growing ...
(Date:3/30/2017)... The research team of The Hong Kong ... identification by adopting ground breaking 3D fingerprint minutiae recovery and matching ... and accuracy for use in identification, crime investigation, immigration control, security ... ... A research team led by ...
Breaking Biology News(10 mins):